Willing to avoid pregnancy or fathering children.
Adequate performance status: children < -Lansky score >= ; children >= -Karnofsky >=  (except for posterior fossa syndrome)
Willingness to avoid pregnancy or fathering children
Men able to father children who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception from the time of signing consent and until  months after last dose of study therapy; men able to father children are defined as those who are not surgically sterile (i.e. patient has not had a vasectomy)
Patient is pregnant or breastfeeding, or plans to become pregnant or father children from time of signing consent and lasting until  months after the last dose of trial treatment
Children under the age of 
Subjects close household contacts include children less than the age of three
Special classes of subjects such as fetuses, pregnant women, children, prisoners, institutionalized individuals, or others who are likely to be vulnerable
Because no dosing or adverse event data are currently available on the use of enzalutamide and CRLX in patients <  years of age and prostate cancer is not common in children <  years of age, children are excluded from this study.
Men who intend to father children during the study or within  months afterward are excluded
Men able to father children who are sexually active with WOCBP must agree to use at least  methods of acceptable contraception from the time of signing consent and until  months after patients last dose of protocol-indicated treatment; men able to father children are defined as those who are not surgically sterile (i.e. patient has not had a vasectomy)
Children are excluded from this study, but will be eligible for future pediatric trials
Men who are expecting to father children within the research period
Children are excluded from this study
Normal serum creatinine based on age/gender as defined by Seattle Children's Hospital (SCH) chemistry lab
Children (<  years of age), pregnant women, University of California employees or students, or prisoners will be excluded from this study
Willingness to avoid pregnancy or fathering children.
Willingness to avoid pregnancy or fathering children as per protocol-defined criteria.
Individuals who are not yet adults (infants, children, teenagers)
Children are excluded from this study, but will be eligible for future pediatric trials
Children less than  months of age at the time of definitive surgery with or without measurable radiographic residual tumor with M stage medulloblastoma will be eligible for study entry
Willingness to avoid pregnancy or fathering children
Lack of parents'/guardian's informed consent for children who are minors.
Patients will be staged for risk classification and treatment at diagnosis using Children's Oncology Group (COG) staging guidelines
Enrollment on a protocol (Children's Oncology Group [COG] or other) which restricts proposed dose modifications
Subjects must be>/=  years of age at the time of informed consent, because no dosing or adverse event data are currently available on the use of eltrombopag in children.
DONOR: Children greater than or equal to  years of age who have not provided informed assent in the presence of a parent and an attending physician who is not a member of the recipients care team
Children are excluded from this study
No desire or plans to father new children during the study and/or have a prior vasectomy
Because no dosing or adverse event data are currently available on the use of ENMD- in patients < years of age, children are excluded from this study but will be eligible for future pediatric single-agent trials, if applicable.
Age initiated after limitation -  years or older. A separate pediatric study is proposed to evaluate tolerance to the drug in children.
persistent cardiac tachyarrhythmia >/minute, or persistent bradyarrythmia < /minute, or age appropriate criteria for younger children,
Diagnosis of ALL, in first remission; enrollment on a Children Oncology Group (COG) therapeutic study for ALL is not required
Children
Families of all children <  years of age admitted to the hospital during the study period who screen positive for secondhand smoke exposure
Families of all children who have at least one custodial parent smoker
Families of all children who are in the hospital for >=  hours
Children in foster care or with unclear custody (i.e. children admitted with non-accidental trauma)
Vulnerable population: adults unable to consent, individuals who are not yet adults (infants, children, teenagers), pregnant women, and prisoners
CHILDREN
Children aged - will assent to participate in the research study by signing a separate assent form
INCLUSION CRITERIA FOR PARENTS: Parents of children who are aged - years
INCLUSION CRITERIA FOR PARENTS: Parents of children who have been diagnosed with new malignancy between - weeks prior
INCLUSION CRITERIA FOR PARENTS: Parents of children who are scheduled to receive cancer-directed therapy at Seattle Children's Hospital
INCLUSION CRITERIA FOR PATIENTS: Child who are scheduled to receive cancer-directed therapy at Seattle Children's Hospital
No patients will be enrolled from vulnerable populations, including neonates, children, prisoners, or institutionalized individuals
Has initiated treatment as part of an active St. Jude Children's Research Hospital (SJCRH) treatment plan
Caregivers with children (patients) who are younger than  years of age may be eligible to participate even though their children are too young to assent or participate themselves
SUBJECT: Children diagnosed with brain tumor in childhood.
Vulnerable populations: there is no inclusion of fetuses, neonates, children, prisoners, institutionalized individuals, or others who may be considered vulnerable populations, except that it is possible that a subject might be pregnant
A St Jude Life participant who was previously treated at St. Jude Children's Research Hospital (SJCRH)
AYA is not married and has no children
Pediatric patients with ALL diagnosis, treated at the University of Minnesota Amplatz\n             Children's Hospital or Children's Hospitals and Clinics of Minnesota
Patient being treated at St. Jude Children's Research Hospital
English speaking parents of children ages  to  years who are admitted to the hospital for a stem cell transplant
First-degree relatives (parents, siblings and adult children >=  years of age) of the CRC participants who do not have LS
Individuals who are not yet adults (infants, children, teenagers)
Be willing to avoid pregnancy or fathering children.
CHILDREN
Multiple children from the same family are eligible to participate in the study
Undecided parents ( years and older) whose children are - year old patients who have not begun the HPV vaccine series.
Patients undergoing other interventions to prevent CLABSI (e.g. Children's Oncology Group [COG] ACCL with chromogranin [CHG], antimicrobial lock therapy, etc.) are ineligible
CHILDREN
CHILDREN
Patients under the care of a St. Jude Children's Research Hospital (SJCRH) physician
Children
Women, children, fetuses, neonates, or prisoners are not included in this research study
Vulnerable patient populations:\r\n* Patients unable to participate in the consent process (children and neonates)
Children will be excluded from this study
Children, pregnant women, Stanford employees or students, or prisoners will be excluded from this study
No vulnerable populations will be enrolled (prisoners, children, pregnant females or institutionalized individuals)
Children will not be included in the study. The pattern of disease and symptoms are different in children than in an adult population. The web-based tool was designed based on the symptom experience of adults with cancer
Vulnerable Populations\r\n* The following groups will be excluded from participation:\r\n** Children\r\n** Decisionally impaired adults\r\n** Prisoners\r\n** Pregnant women
